Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.43 |
| ▸ | PTAFR | P25105 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607083 | 0.91 | MKNK1 (0.50) | CTSLCTSSCTSBCTSVPTAFR | |
| SCHEMBL2933259 | 0.89 | LMNA (0.50) | GPR132LMNA | |
| SCHEMBL619140 | 0.87 | HDAC8 (0.45) | — | |
| SCHEMBL2930310 | 0.84 | CTSA (0.48) | CTSLPTAFRCTSK | |
| SCHEMBL606551 | 0.84 | CTSL (0.48) | CTSLCTSSCTSBCTSVKMO | |
| SCHEMBL3174593 | 0.82 | PSMB5 (0.57) | CTSLCTSSCTSBCTSVKMO | |
| Hydrochloric Acid SCHEMBL1326503 | 0.81 | PSMB5 (0.56) | CTSLCTSSCTSBCTSVCTSK | |
| Hydrochloric Acid SCHEMBL1326505 | 0.79 | CTSL (0.42) | CTSLCTSSCTSBCTSVKMO | |
| SCHEMBL2932701 | 0.79 | HCK (0.39) | CTSSCTSB | |
| SCHEMBL610095 | 0.78 | NPC1 (0.52) | CTSLCTSSCTSBCTSKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | CTSL 1694/4885CTSS 816/4885CTSB 303/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | CTSL 1694/4885CTSS 816/4885CTSB 303/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | CTSL 1694/4885CTSS 816/4885CTSB 303/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | CTSL 1694/4885CTSS 816/4885CTSB 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.